BHRT Delivery Methods: 5-Part Prescriber Guide With Clinical Decision Matrix

Selecting the right BHRT delivery method requires understanding patient lifestyle, compliance factors, and therapeutic goals. No single delivery route fits every patient – and the provider who can match formulation to individual profile is better positioned to support patient adherence and reduce unnecessary dosing adjustments. I’ve spent years working alongside compounding pharmacy clinical teams, and the patterns are consistent: providers who approach BHRT delivery selection with a structured framework tend to see stronger patient engagement, fewer mid-protocol pivots, and more consistent follow-through on the prescribing plan.

This guide walks through each compounded BHRT delivery method available through 503A compounding pharmacies, the clinical considerations for each, and a decision matrix to support your prescribing workflow. All compounded BHRT formulations referenced are not FDA-approved and are prepared by prescription for individual patients.

1. BHRT Prescribing Considerations for Women’s Health Providers

Compounded bioidentical hormone replacement therapy gives prescribers flexibility that commercial hormone products don’t. The ability to adjust individual hormone types, concentrations, and delivery formats within a single prescription is the defining clinical advantage. That flexibility also places the prescribing burden squarely on the provider.

Before evaluating delivery methods, providers should have a clear picture of four baseline factors:

• Hormone panel and symptom profile: Baseline labs guide whether the priority is estradiol, progesterone, testosterone, DHEA, or a combination. Symptoms alone are not sufficient to drive prescribing decisions.
• Absorption variability and metabolic factors: Individual differences in skin permeability, gastrointestinal function, and hepatic metabolism affect how each patient processes a given delivery route. What works predictably in one patient may be inconsistent in another.
• Compliance history and lifestyle: A patient who travels frequently has different needs than one with a stable daily routine. Application-based methods require consistency.
• Contraindication screening: History of thromboembolic events, hormone-sensitive conditions, and current medications should be documented and reviewed before initiating any compounded BHRT formulation. Providers are solely responsible for determining appropriateness for each individual patient.

MediVera’s compounded BHRT formulations span topical creams, oral capsules, sublingual troches, and injectable solutions. For a full overview of available hormone replacement preparations, see our hormone replacement therapy options.

2. Topical and Cream Formulations: Absorption and Compounding Customization

Topical compounded BHRT – applied as a cream, gel, or lotion – is among the most prescribed delivery methods in functional and integrative medicine practices. The compounding advantage here is substantial: concentrations, base formulations, and hormone combinations can be individualized in ways no commercial topical product permits.

Absorption Considerations

Transdermal absorption bypasses first-pass hepatic metabolism, which is a meaningful clinical distinction from oral delivery. Estradiol and testosterone absorb well through skin; progesterone absorption via topical route is more variable and a subject of ongoing clinical discussion among practitioners.

Application site matters. Scrotal skin and inner wrist have higher permeability than outer arm or thigh. Providers should specify application site on the prescription and counsel patients on rotation to avoid receptor saturation at any single site.

Compounding Customization Options

• Hormone combinations: Bi-est (estradiol + estriol) and tri-est formulations can be compounded to specific ratios based on clinical judgment and patient response.
• Base selection: Lipophilic bases, transdermal penetration enhancers, and alcohol-free formulations can be specified to match patient skin tolerance and absorption goals.
• Concentration flexibility: Doses not available commercially can be compounded to the prescriber’s specifications.

Patient Selection Profile

• Patients who prefer non-invasive administration
• Patients who require customized hormone ratios or concentrations
• Patients with consistent daily routines who will apply at the same time each day
• New BHRT patients where dose titration over time is anticipated

Compliance Considerations

Daily application is the primary compliance variable. Providers should discuss skin transfer risk with patients who have close physical contact with children or partners – gloves or application site covering reduces this risk during the absorption window. MediVera’s compounding team can prepare formulations in packaging that supports accurate dosing and reduces handling variance.

3. Injection Protocols: Frequency, Consistency, and Patient Preference

Compounded injectable BHRT – most commonly estradiol cypionate, estradiol valerate, or testosterone cypionate in oil-based suspensions – provides reliable systemic delivery with predictable pharmacokinetics. For providers managing patients on testosterone-inclusive BHRT protocols, injectables offer a level of dose control that topical methods can’t always match.

Protocol Considerations

• Frequency: Injection frequency varies by ester and clinical goal. Weekly injections reduce peak-to-trough fluctuation compared to bi-weekly or monthly protocols. Providers should consider that visible symptom cycling often correlates with dosing interval – shorter intervals typically produce more consistent patient-reported wellbeing.
• Administration route: Intramuscular and subcutaneous injection protocols each have clinical rationale. Subcutaneous administration of testosterone has gained adoption in women’s health protocols for its lower peak-to-trough variance relative to IM injection.
• Self-administration vs. in-office: Patients who self-inject require proper training, appropriate needle gauge selection for their prescribed oil-based formulation, and documentation of training. In-office injection is appropriate for patients who are not candidates for self-administration.

Patient Selection Profile

• Patients with documented absorption inconsistency on topical formulations
• Patients comfortable with self-injection who benefit from dose flexibility over time
• Patients on testosterone-inclusive protocols where measurable serum levels guide ongoing management
• Patients in practices with existing in-office injection infrastructure

Monitoring Considerations

Injectable protocols lend themselves well to monitoring by serum level, timed to the midpoint between doses to capture trough levels. This gives providers a reproducible window for lab interpretation and dosing adjustment conversations.

4. Sublingual and Oral Delivery Options

Sublingual and oral compounded BHRT formulations – troches, lozenges, capsules, and drops – remain clinically useful for specific patient profiles and hormone types. Understanding the pharmacokinetic distinctions between sublingual and oral routes is essential for appropriate prescribing.

Sublingual Troches and Lozenges

Sublingual delivery allows hormone absorption directly through the oral mucosa, partially bypassing first-pass hepatic metabolism depending on how much of the dose is swallowed vs. absorbed sublingually. Estradiol, progesterone, and testosterone can all be compounded into troche form at individualized concentrations.

Clinical considerations for sublingual delivery:

• Absorption can be variable depending on patient adherence to the sublingual technique – patients who swallow early shift more of the dose to the hepatic metabolism pathway.
• Dosing is typically twice daily for many hormone formulations, which requires patient education on consistent timing.
• Troches can be flavored to improve palatability, which compounding pharmacies can accommodate on prescription.

Oral Capsules

Oral micronized progesterone has the most established evidence base among oral compounded BHRT formulations. It undergoes hepatic first-pass metabolism that produces metabolites with sedative properties – a characteristic that can be therapeutically useful when prescribed at bedtime for patients with concurrent sleep complaints. Oral estradiol formulations are less commonly used in compounding due to the first-pass effect significantly altering the estrogen metabolite profile.

Patient Selection Profile

• Patients with needle aversion who are not candidates for topical application
• Patients where oral micronized progesterone at bedtime aligns with sleep management goals
• Patients with good daily adherence who can maintain consistent dosing timing
• Adjunctive use when one hormone in a multi-hormone protocol is best delivered orally

5. Clinical Decision-Making Framework for BHRT Delivery Selection

The clinical decision matrix below consolidates patient-level factors into a structured prescribing framework. It is not a substitute for individual clinical judgment – it’s a starting point for the provider conversation about delivery route selection.

BHRT Delivery Method: Clinical Decision Matrix

This matrix is for clinical reference only. Individual patient assessment and provider judgment govern all prescribing decisions. Compounded BHRT is not FDA-approved.

Applying the Framework in Practice

Start with compliance history and lifestyle before moving to absorption or pharmacokinetic considerations. A patient who will not apply a cream consistently will not benefit from its theoretical absorption advantages.

For patients who are new to BHRT or whose optimal dose has not yet been established, topical creams and injectables offer dose adjustability that is easier to manage over time. The BHRT delivery selection conversation belongs in the prescribing visit, not the follow-up – patients who understand why their delivery method was chosen are more adherent and more likely to stay in your program.

For more on how compounded BHRT is prepared and what quality standards govern formulation, MediVera’s PCAB accreditation overview covers the standards that apply to every compound leaving a PCAB-accredited facility. The BHRT for women overview provides additional context on hormone roles and patient education language.

Partner With a Compounding Pharmacy Built for BHRT Providers

Compounded BHRT prescribing is only as strong as the pharmacy partnership behind it. MediVera Compounding Pharmacy brings PCAB dual accreditation in sterile and non-sterile compounding, 25+ years of BHRT formulation experience, and a clinical team that supports providers through dosing questions, formulation decisions, and patient education resources.

We prepare topical creams, sublingual troches, oral capsules, and injectable solutions – all compounded to prescription specifications and shipped within 48 hours of patient confirmation to patients across 43+ states. Our hormone replacement therapy prescribing portal gives providers a direct path to prescription submission, product catalog access, and dedicated account support.

Contact our BHRT clinical team.

This article is for informational purposes only and is not medical advice. Always consult a healthcare professional before starting any treatment. Compounded medications referenced are not reviewed by the FDA for safety or effectiveness and are prepared by prescription for individual patients. Providers are solely responsible for determining their appropriateness.